Table. Frequency and Source of Discrepancies in Tumor Stage Among Primary Cutaneous Melanomas Within SEER Registries, 2004-2017.
Years of diagnosis | No. of discrepancies for each supplementary staging variable | Total discrepancies by resulting stage changea | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Breslow depth (SSF1)b | Ulceration status (SSF2)b | Presence of mitoses (SSF7)b | Regional nodes positivec | Clinical lymph node status (SSF3)c | Other distant metastasisd | SEER combined summary stage 2000e | Not stage changing | Stage increase | Stage decrease | |
Introduction of AJCC 6th edition staging to SEER | ||||||||||
2004 | 0 | 0 | NA | 20 | 4 | 0 | 129 | 13 | 118 | 22 |
2005 | 2 | 0 | NA | 12 | 7 | 0 | 107 | 12 | 101 | 15 |
2006 | 2 | 0 | NA | 12 | 8 | 0 | 111 | 12 | 110 | 11 |
2007 | 3 | 0 | NA | 15 | 6 | 0 | 106 | 9 | 105 | 16 |
2008 | 0 | 0 | NA | 25 | 13 | 0 | 111 | 16 | 109 | 24 |
2009 | 7 | 0 | NA | 25 | 22 | 0 | 115 | 30 | 109 | 30 |
Introduction of AJCC 7th edition staging to SEER | ||||||||||
2010 | 29 | 356 | 355 | 20 | 28 | 0 | 118 | 23 | 121 | 762 |
2011 | 108 | 262 | 261 | 35 | 39 | 0 | 133 | 25 | 156 | 657 |
2012 | 134 | 217 | 217 | 60 | 91 | 0 | 243 | 51 | 304 | 607 |
2013 | 175 | 203 | 209 | 58 | 104 | 0 | 218 | 70 | 287 | 610 |
2014 | 131 | 170 | 175 | 61 | 113 | 0 | 240 | 103 | 282 | 505 |
2015 | 129 | 151 | 152 | 88 | 119 | 0 | 224 | 99 | 265 | 499 |
Introduction of UICC 7th edition staging to SEER | ||||||||||
2016 | 0 | 105 | 713 | 72 | 38 | 3 | 202 | 0 | 811 | 322 |
2017 | 0 | 62 | 532 | 70 | 58 | 3 | 163 | 0 | 655 | 233 |
Totals | 720 | 1526 | 2614 | 573 | 650 | 6 | 2220 | 463 | 3533 | 4313 |
Abbreviations: AJCC, American Joint Committee on Cancer; NA, not applicable; SEER, Surveillance, Epidemiology, and End Results Program; SSF, site-specific factor; UICC, Union for International Cancer Control.
Stage-changing discrepancies are those that result in an increase or decrease to the tumor stage listed (eg, stage IIIB T4aN1bM0 tumor with site-specific factor 3 coded as “nodes negative on pathologic examination” would imply decrease to stage II).
Mismatch with T (tumor) component of TNM cancer staging system.
Mismatch with N (node) component of TNM cancer staging system.
Mismatch with M (metastasis) component of TNM cancer staging system.
The SEER Combined Summary Stage 2000 variable allowed for comparison of all 3 TNM components because it incorporates distant nodes/sites involved, regional by nodes involved, regional by extension only, regional by nodes involved and extension, regional not otherwise specified, and localized only.